Efficacy and safety of probucol plus telmisartan for type-2 diabetic nephropathy: a multicentre, prospective, randomised, double-blind, double-dummy, controlled trial.

Trial Profile

Efficacy and safety of probucol plus telmisartan for type-2 diabetic nephropathy: a multicentre, prospective, randomised, double-blind, double-dummy, controlled trial.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Sep 2013

At a glance

  • Drugs Probucol (Primary) ; Telmisartan (Primary)
  • Indications Diabetic nephropathies; Renal failure
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
    • 16 Oct 2012 Status changed from not yet recruiting to completed as reported by Chinese Clinical Trial Register.
    • 21 May 2012 Planned end date changed from 1 Dec 2011 to 30 Jun 2012 as reported by Chinese Clinical Trial Register.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top